TY - JOUR
T1 - An update of molecular findings in uterine tumor resembling ovarian sex cord tumor and GREB1-rearranged uterine sarcoma with variable sex-cord differentiation
AU - Kao, Yu Chien
AU - Lee, Jen Chieh
N1 - Publisher Copyright:
© 2020 Wiley Periodicals LLC.
PY - 2021/3
Y1 - 2021/3
N2 - Uterine tumor resembling ovarian sex cord tumor (UTROSCT) is a uterine mesenchymal tumor defined histologically by showing sex cord-like growth patterns, such as sheets, nests, trabeculae, cords, or tubules, with/without Sertoli-like or Leydig-like components, and immunohistochemically by exhibiting variable sex cord markers in addition to epithelial, myogenic, and sex hormone markers. Recent years have seen the emergence in UTROSCT of novel fusion genes that involve key genes in sex hormone pathways, including ESR1 and GREB1 as the 5′ partner, and (co)activator oncogenes, particularly NCOA1-3, as the 3′ partner. While the identification of similar fusions in the majority of cases serves as a strong argument for UTROSCT to be a distinct entity, there is no denying significant clinicopathologic heterogeneity within the disease spectrum, which might to some extent correlate with the different fusion types. The current review gives a summary of the recently identified fusions in UTROSCT, along with their possible clinicopathologic relevance. Also discussed are unsolved issues including the relationship between UTROSCT and so-called GREB1-rearranged uterine sarcoma as well as other uterine mesenchymal tumors harboring similar fusions.
AB - Uterine tumor resembling ovarian sex cord tumor (UTROSCT) is a uterine mesenchymal tumor defined histologically by showing sex cord-like growth patterns, such as sheets, nests, trabeculae, cords, or tubules, with/without Sertoli-like or Leydig-like components, and immunohistochemically by exhibiting variable sex cord markers in addition to epithelial, myogenic, and sex hormone markers. Recent years have seen the emergence in UTROSCT of novel fusion genes that involve key genes in sex hormone pathways, including ESR1 and GREB1 as the 5′ partner, and (co)activator oncogenes, particularly NCOA1-3, as the 3′ partner. While the identification of similar fusions in the majority of cases serves as a strong argument for UTROSCT to be a distinct entity, there is no denying significant clinicopathologic heterogeneity within the disease spectrum, which might to some extent correlate with the different fusion types. The current review gives a summary of the recently identified fusions in UTROSCT, along with their possible clinicopathologic relevance. Also discussed are unsolved issues including the relationship between UTROSCT and so-called GREB1-rearranged uterine sarcoma as well as other uterine mesenchymal tumors harboring similar fusions.
KW - ESR1
KW - GREB1
KW - uterine sarcoma
KW - uterine tumor resembling ovarian sex cord tumor
UR - http://www.scopus.com/inward/record.url?scp=85096769769&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85096769769&partnerID=8YFLogxK
U2 - 10.1002/gcc.22909
DO - 10.1002/gcc.22909
M3 - Review article
C2 - 33099842
AN - SCOPUS:85096769769
SN - 1045-2257
VL - 60
SP - 180
EP - 189
JO - Genes Chromosomes and Cancer
JF - Genes Chromosomes and Cancer
IS - 3
ER -